Used primarily as a key intermediate in the synthesis of immunomodulatory drugs, particularly in the development of cereblon E3 ligase modulators. It plays a critical role in targeted protein degradation therapies, including the production of compounds like lenalidomide derivatives. Its structure enables selective binding to cereblon, making it valuable in creating molecules that can redirect the ubiquitin-proteasome system for degradation of disease-related proteins. Widely applied in pharmaceutical research for cancer treatment, especially in hematological malignancies such as multiple myeloma and myelodysplastic syndromes. Also utilized in the design of PROTACs (proteolysis-targeting chimeras) due to its ability to engage E3 ligase machinery effectively.